Chuck Royce's INDV Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 9,900 shares of Indivior Pharmaceuticals, Inc. (INDV) worth $301,752, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Chuck Royce has maintained this position in INDV for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 61,333 shares. Largest reduction occurred in Q1 2026, reducing 297,957 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Indivior Pharmaceuticals (INDV) Holding Value Over Time
Track share changes against reported price movement
Quarterly Indivior Pharmaceuticals (INDV) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -297,957 | Reduce 96.78% | 9,900 | $30.48 |
| Q4 2025 | +61,333 | Add 24.88% | 307,857 | $35.88 |
| Q3 2025 | +246,524 | New Buy | 246,524 | $24.11 |
Chuck Royce's Indivior Pharmaceuticals Investment FAQs
Chuck Royce first purchased Indivior Pharmaceuticals, Inc. (INDV) in Q3 2025, acquiring 246,524 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Indivior Pharmaceuticals, Inc. (INDV) for 3 quarters since Q3 2025.
Chuck Royce's largest addition to Indivior Pharmaceuticals, Inc. (INDV) was in Q3 2025, adding 246,524 shares worth $5.94 M.
According to the latest 13F filing for Q1 2026, Chuck Royce's firm, Royce & Associates Lp, owns 9,900 shares of Indivior Pharmaceuticals, Inc. (INDV), valued at approximately $301,752.
As of the Q1 2026 filing, Indivior Pharmaceuticals, Inc. (INDV) represents approximately 0.00% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Indivior Pharmaceuticals, Inc. (INDV) was 307,857 shares, as reported at the end of Q4 2025.